Zolgensma's flouted expectations, and insurers are on board
The science of gene therapy is promising — but the stunning price tags have called into question whether these treatments can ever be financially viable for patients and insurers alike. But so far, Zolgensma, the $2.1 million Novartis treatment for spinal muscular atrophy, appears to be delivering.
The company announced yesterday that the treatment had brought in about $160 million last quarter alone, surpassing analyst expectations. Furthermore, 99% of the SMA patients who qualified for Zolgensma got coverage of the one-time therapy. The company has been able to strike deals with health plans to cover the treatment — saying that agreements are in place to cover 90% of the patients who are commercially insured, as well as for the 30% covered by Medicaid.
Read more.
The company announced yesterday that the treatment had brought in about $160 million last quarter alone, surpassing analyst expectations. Furthermore, 99% of the SMA patients who qualified for Zolgensma got coverage of the one-time therapy. The company has been able to strike deals with health plans to cover the treatment — saying that agreements are in place to cover 90% of the patients who are commercially insured, as well as for the 30% covered by Medicaid.
Read more.
.png)
No hay comentarios:
Publicar un comentario